|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
28
|
|
pubmed:dateCreated |
2008-9-30
|
|
pubmed:abstractText |
Studies indicate that castration-resistant prostate cancer (CRPC) remains driven by ligand-dependent androgen receptor (AR) signaling. To evaluate this, a trial of abiraterone acetate-a potent, selective, small-molecule inhibitor of cytochrome P (CYP) 17, a key enzyme in androgen synthesis-was pursued.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:AttardGerhardtG,
pubmed-author:BarrettMaryM,
pubmed-author:ClarkJeremyJ,
pubmed-author:CooperColin SCS,
pubmed-author:DearnaleyDavidD,
pubmed-author:DowsettMitchM,
pubmed-author:FolkerdElizabethE,
pubmed-author:KayeStan BSB,
pubmed-author:LeeGloriaG,
pubmed-author:MartinsVanessaV,
pubmed-author:ParkerChristopherC,
pubmed-author:RaynaudFlorenceF,
pubmed-author:ReidAlison H MAH,
pubmed-author:SettatreeSarahS,
pubmed-author:YapTimothy ATA,
pubmed-author:de BonoJohann SJS
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
26
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4563-71
|
|
pubmed:dateRevised |
2009-12-11
|
|
pubmed:meshHeading |
pubmed-meshheading:18645193-Adenocarcinoma,
pubmed-meshheading:18645193-Administration, Oral,
pubmed-meshheading:18645193-Aged,
pubmed-meshheading:18645193-Aged, 80 and over,
pubmed-meshheading:18645193-Androstenols,
pubmed-meshheading:18645193-Castration,
pubmed-meshheading:18645193-Disease Progression,
pubmed-meshheading:18645193-Humans,
pubmed-meshheading:18645193-Male,
pubmed-meshheading:18645193-Middle Aged,
pubmed-meshheading:18645193-Neoplasms, Hormone-Dependent,
pubmed-meshheading:18645193-Prospective Studies,
pubmed-meshheading:18645193-Prostatic Neoplasms,
pubmed-meshheading:18645193-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
|
|
pubmed:affiliation |
Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
